Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure

References

• Bozkurt B, Hershberger RE, Butler J, et al. ACC/AHA key data elements and definitions for heart failure: a report of the American College of Cardiology/American heart Association Task Force on clinical data Standards (Writing Committee to develop clinical data Standards for heart failure). Circ Cardiovasc Qual Outcomes. 2021 Apr;14(4):e000102. doi: 10.1161/HCQ.0000000000000102
   PubMed Web of Science ®Google Scholar
• Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368–378. doi: 10.1038/nrcardio.2016.25
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012 Dec 15;380(9859):2163–96. doi: 10.1016/S0140-6736(12)61729-2
   PubMed Web of Science ®Google Scholar
• Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction SOLVD Investigators. Circulation. 1996 Aug 15;94(4):690–697. doi: 10.1161/01.CIR.94.4.690
   PubMed Web of Science ®Google Scholar
• Francis GS, McDonald KM, Cohn JN. Neurohumoral activation in preclinical heart failure. Remodeling and the potential for intervention. Circulation. 1993 May;87(5 Suppl):Iv90–6.
   PubMed Web of Science ®Google Scholar
• Magri P, Rao MA, Cangianiello S, et al. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Circulation. 1998 Dec 22–29;98(25):2849–54. doi: 10.1161/01.CIR.98.25.2849
   PubMed Web of Science ®Google Scholar
• Mastromarino V, Volpe M, Musumeci MB, et al. Erythropoietin and the heart: facts and perspectives. Clin Sci (Lond). 2011 Jan;120(2):51–63. doi: 10.1042/CS20100305
   PubMed Web of Science ®Google Scholar
• Shenker Y, Sider RS, Ostafin EA, et al. Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. J Clin Invest. 1985 Oct;76(4):1684–1687. doi: 10.1172/JCI112154
   PubMed Web of Science ®Google Scholar
• Sullivan RD, Mehta RM, Tripathi R, et al. Renin Activity in Heart Failure with Reduced Systolic Function—New Insights. Int J Mol Sci. 2019 Jun 28;20(13):3182. doi: 10.3390/ijms20133182
   PubMed Web of Science ®Google Scholar
• Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017 Jan;14(1):30–38. doi: 10.1038/nrcardio.2016.163
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF study group. JAMA. 2000 Mar 8;283(10):1295–302. doi: 10.1001/jama.283.10.1295
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651–8. doi: 10.1056/NEJM200105313442201
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14(8):803–69. doi: 10.1093/eurjhf/hfs105
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):293–302.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003 Sep 6;362(9386):777–781. doi: 10.1016/S0140-6736(03)14285-7
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011 Jan 6;364(1):11–21. doi: 10.1056/NEJMoa1009492
   PubMed Web of Science ®Google Scholar
• Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: population based cohort study. BMJ. 2019;364:l223. doi: 10.1136/bmj.l223
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (Esc)developed with the special contribution of the heart failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129–2200. doi: 10.1093/eurheartj/ehw128
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American heart Association Task Force on clinical practice guidelines and the heart failure Society of America. Circulation. 2017 Aug 8;136(6):e137–e161. doi: 10.1161/CIR.0000000000000509
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Isobe M, Ito H, et al. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure　- digest version. Circ J. 2019 Sep 25;83(10):2084–2184. doi: 10.1253/circj.CJ-19-0342
   PubMed Web of Science ®Google Scholar
• Sudoh T, Minamino N, Kangawa K, et al. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990 Apr 30;168(2):863–870. doi: 10.1016/0006-291X(90)92401-K
   PubMed Web of Science ®Google Scholar
• Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991 Apr;87(4):1402–1412. doi: 10.1172/JCI115146
   PubMed Web of Science ®Google Scholar
• de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981 Jan 5;28(1):89–94. doi: 10.1016/0024-3205(81)90370-2
   PubMed Web of Science ®Google Scholar
• Sangaralingham SJ, Kuhn M, Cannone V, et al. Natriuretic peptide pathways in heart failure: further therapeutic possibilities. Cardiovasc Res. 2023 Feb 3;118(18):3416–3433. doi: 10.1093/cvr/cvac125
   PubMed Web of Science ®Google Scholar
• Chen Y, Burnett JC Jr. Biochemistry, therapeutics, and biomarker implications of neprilysin in cardiorenal disease. Clin Chem. 2017 Jan;63(1):108–115. doi: 10.1373/clinchem.2016.262907
   PubMed Web of Science ®Google Scholar
• Kuhn M. Molecular physiology of membrane guanylyl cyclase receptors. Physiol Rev. 2016, Apr;96(2):751–804. doi: 10.1152/physrev.00022.2015
   PubMed Web of Science ®Google Scholar
• Abassi Z, Khoury EE, Karram T, et al. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. doi: 10.3389/fcvm.2022.933215
   PubMed Web of Science ®Google Scholar
• Melé M, Ferreira PG, Reverter F, et al. Human genomics. The human transcriptome across tissues and individuals. Science. 2015 May 8;348(6235):660–665. doi: 10.1126/science.aaa0355
   PubMed Web of Science ®Google Scholar
• Nagase M, Katafuchi T, Hirose S, et al. Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats. J Hypertens. 1997 Nov;15(11):1235–1243. doi: 10.1097/00004872-199715110-00007
   PubMed Web of Science ®Google Scholar
• Potter LR. Domain analysis of human transmembrane guanylyl cyclase receptors: implications for regulation. Front Biosci. 2005 May 1;10(1–3):1205–1220. doi: 10.2741/1613
   PubMedGoogle Scholar
• Ashman DF, Lipton R, Melicow MM, et al. Isolation of adenosine 3‘, 5’-monophosphate and guanosine 3‘, 5’-monophosphate from rat urine. Biochem Biophys Res Commun. 1963 May 22;11:330–4. doi: 10.1016/0006-291X(63)90566-7
   PubMed Web of Science ®Google Scholar
• Schlossmann J, Feil R, Hofmann F. Insights into cGMP signalling derived from cGMP kinase knockout mice. Front Biosci. 2005 May 1;10:1279–89. doi: 10.2741/1618
   PubMed Web of Science ®Google Scholar
• Emdin M, Aimo A, Castiglione V, et al. Targeting cyclic guanosine monophosphate to treat heart failure: JACC review Topic of the Week. J Am Coll Cardiol. 2020 Oct 13;76(15):1795–1807. doi: 10.1016/j.jacc.2020.08.031
   PubMed Web of Science ®Google Scholar
• Lommi J, Pulkki K, Koskinen P, et al. Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure. Eur Heart J. 1997 Oct;18(10):1620–1625. doi: 10.1093/oxfordjournals.eurheartj.a015142
   PubMed Web of Science ®Google Scholar
• van Heerebeek L, Hamdani N, Falcão-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012 Aug 14;126(7):830–9. doi: 10.1161/CIRCULATIONAHA.111.076075
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019 Feb 7;380(6):539–548. doi: 10.1056/NEJMoa1812851
   PubMed Web of Science ®Google Scholar
• Pieske B, Wachter R, Shah SJ, et al. Effect of Sacubitril/Valsartan vs standard Medical therapies on plasma NT-proBNP Concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial. JAMA. 2021 Nov 16;326(19):1919–1929. doi: 10.1001/jama.2021.18463
   PubMed Web of Science ®Google Scholar
• Moe GW, Forster C, de Bold AJ, et al. Pharmacokinetics, hemodynamic, renal, and neurohormonal effects of atrial natriuretic factor in experimental heart failure. Clin Invest Med. 1990 Jun;13(3):111–118.
   PubMed Web of Science ®Google Scholar
• Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature. 1986 Dec 4–10;324(6096):473–476. doi: 10.1038/324473a0
   PubMed Web of Science ®Google Scholar
• Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature. 1987 Apr 16–22;326(6114):697–698. doi: 10.1038/326697a0
   PubMed Web of Science ®Google Scholar
• Light DB, Corbin JD, Stanton BA. Dual ion-channel regulation by cyclic GMP and cyclic GMP-dependent protein kinase. Nature. 1990 Mar 22;344(6264):336–339. doi: 10.1038/344336a0
   PubMed Web of Science ®Google Scholar
• Gopi V, Parthasarathy A, Umadevi S, et al. Angiotensin-II down-regulates cardiac natriuretic peptide receptor-A mediated anti-hypertrophic signaling in experimental rat hearts. Indian J Exp Biol. 2013 Jan;51(1):48–55.
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Naruse M, Naruse K, et al. Angiotensin II-dependent down-regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats. Endocrinology. 1996 Mar;137(3):1102–1107. doi: 10.1210/endo.137.3.8603580
   PubMed Web of Science ®Google Scholar
• Carvajal JA, Germain AM, Huidobro-Toro JP, et al. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol. 2000 Sep;184(3):409–420. doi: 10.1002/1097-4652(200009)184:3<409:AID-JCP16>3.0.CO;2-K
   PubMed Web of Science ®Google Scholar
• Chartier L, Schiffrin E, Thibault G, et al. Atrial natriuretic factor inhibits the stimulation of aldosterone secretion by angiotensin ii, acth and potassium in vitro and angiotensin ii-induced steroidogenesis in vivo. Endocrinology. 1984, Nov;115(5):2026–2028. doi: 10.1210/endo-115-5-2026
   PubMed Web of Science ®Google Scholar
• Kudo T, Baird A. Inhibition of aldosterone production in the adrenal glomerulosa by atrial natriuretic factor. Nature. 1984 Dec 20 1985 Jan 2;312(5996):756–7. doi: 10.1038/312756a0
   PubMed Web of Science ®Google Scholar
• Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998 Feb 15;101(4):812–818. doi: 10.1172/JCI119883
   PubMed Web of Science ®Google Scholar
• Pandey KN. Genetic ablation and guanylyl cyclase/natriuretic peptide receptor-A: impact on the pathophysiology of cardiovascular dysfunction. Int J Mol Sci. 2019 Aug 14;20(16):3946. doi: 10.3390/ijms20163946
   PubMed Web of Science ®Google Scholar
• Hayashi D, Kudoh S, Shiojima I, et al. Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. Biochem Biophys Res Commun. 2004 Sep 10;322(1):310–319. doi: 10.1016/j.bbrc.2004.07.119
   PubMed Web of Science ®Google Scholar
• Fujita S, Shimojo N, Terasaki F, et al. Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor a cascade. Heart Vessels. 2013 Sep;28(5):646–657. doi: 10.1007/s00380-012-0311-0
   PubMed Web of Science ®Google Scholar
• Volpe M, Lembo G, Condorelli G, et al. Converting enzyme inhibition prevents the effects of atrial natriuretic factor on baroreflex responses in humans. Circulation. 1990 Oct;82(4):1214–1221. doi: 10.1161/01.CIR.82.4.1214
   PubMed Web of Science ®Google Scholar
• Itoh T, Nagaya N, Murakami S, et al. C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004 Dec 1;170(11):1204–1211. doi: 10.1164/rccm.200404-455OC
   PubMed Web of Science ®Google Scholar
• Murakami S, Nagaya N, Itoh T, et al. C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2004 Dec;287(6):L1172–7. doi: 10.1152/ajplung.00087.2004
   PubMed Web of Science ®Google Scholar
• Hamad AM, Clayton A, Islam B, et al. Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function. Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L973–83. doi: 10.1152/ajplung.00033.2003
   PubMed Web of Science ®Google Scholar
• Raine AE, Erne P, Bürgisser E, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med. 1986 Aug 28;315(9):533–7. doi: 10.1056/NEJM198608283150901
   PubMed Web of Science ®Google Scholar
• Ibebuogu UN, Gladysheva IP, Houng AK, et al. Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide. Circ Heart Fail. 2011 Mar;4(2):114–20. doi: 10.1161/CIRCHEARTFAILURE.109.895581
   PubMed Web of Science ®Google Scholar
• Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016 Jan;130(2):57–77. doi: 10.1042/CS20150469
   PubMed Web of Science ®Google Scholar
• Dries DL. Process matters: emerging concepts underlying impaired natriuretic peptide system function in heart failure. Circ Heart Fail. 2011 Mar;4(2):107–110. doi: 10.1161/CIRCHEARTFAILURE.111.960948
   PubMed Web of Science ®Google Scholar
• Gorica E, Mohammed SA, Ambrosini S, et al. Epi-Drugs in Heart Failure. Front Cardiovasc Med. 2022;9:923014. doi: 10.3389/fcvm.2022.923014
   PubMed Web of Science ®Google Scholar
• Nemtsova MV, Zaletaev DV, Bure IV, et al. Epigenetic changes in the pathogenesis of rheumatoid arthritis. Front Genet. 2019;10:570. doi: 10.3389/fgene.2019.00570
   PubMed Web of Science ®Google Scholar
• Nebbioso A, Tambaro FP, Dell’aversana C, et al. Cancer epigenetics: moving forward. PLoS Genet. 2018 Jun;14(6):e1007362. doi: 10.1371/journal.pgen.1007362
   PubMed Web of Science ®Google Scholar
• Gidlöf O. Toward a New paradigm for targeted natriuretic peptide enhancement in heart failure. Front Physiol. 2021;12:650124. doi: 10.3389/fphys.2021.650124
   PubMed Web of Science ®Google Scholar
• Gusterson RJ, Jazrawi E, Adcock IM, et al. The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J Biol Chem. 2003 Feb 28;278(9):6838–6847. doi: 10.1074/jbc.M211762200
   PubMed Web of Science ®Google Scholar
• Rosales W, Lizcano F. The histone demethylase JMJD2A modulates the induction of hypertrophy markers in iPSC-Derived cardiomyocytes. Front Genet. 2018;9:14. doi: 10.3389/fgene.2018.00014
   PubMed Web of Science ®Google Scholar
• Kumar P, Tripathi S, Pandey KN. Histone deacetylase inhibitors modulate the transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-a gene: interactive roles of modified histones, histone acetyltransferase, p300, and Sp1. J Biol Chem. 2014 Mar 7;289(10):6991–7002. doi: 10.1074/jbc.M113.511444
   PubMed Web of Science ®Google Scholar
• Kee HJ, Sohn IS, Nam KI, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 2006 Jan 3;113(1):51–59. doi: 10.1161/CIRCULATIONAHA.105.559724
   PubMed Web of Science ®Google Scholar
• Kong Y, Tannous P, Lu G, et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation. 2006 Jun 6;113(22):2579–2588. doi: 10.1161/CIRCULATIONAHA.106.625467
   PubMed Web of Science ®Google Scholar
• Gallo P, Latronico MV, Gallo P, et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res. 2008 Dec 1;80(3):416–24. doi: 10.1093/cvr/cvn215
   PubMed Web of Science ®Google Scholar
• Xie M, Kong Y, Tan W, et al. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation. 2014 Mar 11;129(10):1139–1151. doi: 10.1161/CIRCULATIONAHA.113.002416
   PubMed Web of Science ®Google Scholar
• Kumar P, Periyasamy R, Das S, et al. All-trans retinoic acid and sodium butyrate enhance natriuretic peptide receptor a gene transcription: role of histone modification. Mol Pharmacol. 2014 Jun;85(6):946–957. doi: 10.1124/mol.114.092221
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012 Oct 20;380(9851):1387–1395. doi: 10.1016/S0140-6736(12)61227-6
   PubMed Web of Science ®Google Scholar
• Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010 Apr;50(4):401–14. doi: 10.1177/0091270009343932
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993–1004. doi: 10.1056/NEJMoa1409077
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019 Oct 24;381(17):1609–1620. doi: 10.1056/NEJMoa1908655
   PubMed Web of Science ®Google Scholar
• Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: hormones secreted from the heart. Peptides. 2019 Jan;111:18–25. doi: 10.1016/j.peptides.2018.05.012
   PubMed Web of Science ®Google Scholar
• Zhang X, Gu X, Zhang Y, et al. Corin: A Key Mediator in Sodium Homeostasis, Vascular Remodeling, and Heart Failure. Biology. 2022 May 7;11(5):717. doi: 10.3390/biology11050717
   PubMedGoogle Scholar
• Zaidi SS, Ward RD, Ramanathan K, et al. Possible enzymatic Downregulation of the natriuretic peptide system in patients with reduced systolic function and heart failure: a Pilot study. Biomed Res Int. 2018;2018:7279036. doi: 10.1155/2018/7279036
   PubMed Web of Science ®Google Scholar
• Gladysheva IP, Sullivan RD, Reed GL. Falling corin and ANP activity levels accelerate development of heart failure and cardiac fibrosis. Front Cardiovasc Med. 2023;10:1120487. doi: 10.3389/fcvm.2023.1120487
   PubMed Web of Science ®Google Scholar
• Tripathi R, Wang D, Sullivan R, et al. Depressed corin levels indicate early systolic dysfunction before increases of atrial natriuretic peptide/B-Type natriuretic peptide and heart failure development. Hypertension. 2016 Feb;67(2):362–367. doi: 10.1161/HYPERTENSIONAHA.115.06300
   PubMed Web of Science ®Google Scholar
• Verstreken S, Delrue L, Goethals M, et al. Natriuretic peptide processing in patients with and without left ventricular dysfunction. Int Heart J. 2019 Jan 25;60(1):115–120. doi: 10.1536/ihj.18-012
   PubMed Web of Science ®Google Scholar
• Langenickel TH, Pagel I, Buttgereit J, et al. Rat corin gene: molecular cloning and reduced expression in experimental heart failure. Am J Physiol Heart Circ Physiol. 2004 Oct;287(4):H1516–21. doi: 10.1152/ajpheart.00947.2003
   PubMed Web of Science ®Google Scholar
• Ichiki T, Boerrigter G, Huntley BK, et al. Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol. 2013 Jan 15;304(2):R102–9. doi: 10.1152/ajpregu.00233.2012
   PubMed Web of Science ®Google Scholar
• Ngo DT, Horowitz JD, Sverdlov AL. Heart failure: a corin-deficient state? Hypertension. 2013 Feb;61(2):284–5. doi: 10.1161/HYPERTENSIONAHA.112.196253
   PubMed Web of Science ®Google Scholar
• Pang A, Hu Y, Zhou P, et al. Corin is down-regulated and exerts cardioprotective action via activating pro-atrial natriuretic peptide pathway in diabetic cardiomyopathy. Cardiovasc Diabetol. 2015 Oct 7;14(1):134. doi: 10.1186/s12933-015-0298-9
   PubMedGoogle Scholar
• Gladysheva IP, Wang D, McNamee RA, et al. Corin overexpression improves cardiac function, heart failure, and survival in mice with dilated cardiomyopathy. Hypertension. 2013 Feb;61(2):327–332. doi: 10.1161/HYPERTENSIONAHA.112.193631
   PubMed Web of Science ®Google Scholar
• Tripathi R, Sullivan RD, Fan TM, et al. Cardiac-specific overexpression of Catalytically inactive corin reduces edema, contractile dysfunction, and death in mice with dilated cardiomyopathy. Int J Mol Sci. 2019 Dec 27;21(1):203. doi: 10.3390/ijms21010203
   PubMed Web of Science ®Google Scholar
• Giannessi D, Del Ry S, Vitale RL. The role of endothelins and their receptors in heart failure. Pharmacol Res. 2001 Feb;43(2):111–126. doi: 10.1006/phrs.2000.0758
   PubMed Web of Science ®Google Scholar
• Kalk P, Sharkovska Y, Kashina E, et al. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension. 2011 Apr;57(4):755–63. doi: 10.1161/HYPERTENSIONAHA.110.163972
   PubMed Web of Science ®Google Scholar
• Sakai S, Miyauchi T, Yamaguchi I. Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure. Circulation. 2000 Jun 20;101(24):2849–2853. doi: 10.1161/01.CIR.101.24.2849
   PubMed Web of Science ®Google Scholar
• Mulder P, Barbier S, Monteil C, et al. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure. J Cardiovasc Pharmacol. 2004 Apr;43(4):489–494. doi: 10.1097/00005344-200404000-00003
   PubMed Web of Science ®Google Scholar
• Emoto N, Raharjo SB, Isaka D, et al. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension. 2005, Jun;45(6):1145–1152. doi: 10.1161/01.HYP.0000168944.29525.da
   PubMed Web of Science ®Google Scholar
• Seed A, Kuc RE, Maguire JJ, et al. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13–14):743–748. doi: 10.1016/j.lfs.2012.03.022
   PubMed Web of Science ®Google Scholar
• Dickstein K, De Voogd HJ, Miric MP, et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol. 2004 Jul 15;94(2):237–239. doi: 10.1016/j.amjcard.2004.03.074
   PubMed Web of Science ®Google Scholar
• Naso MF, Tomkowicz B, Perry WL 3rd, et al. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017 Aug;31(4):317–334. doi: 10.1007/s40259-017-0234-5
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhan Q, Huang B, et al. AAV-mediated gene therapy: advancing cardiovascular disease treatment. Front Cardiovasc Med. 2022;9:952755. doi: 10.3389/fcvm.2022.952755
   PubMed Web of Science ®Google Scholar
• Nguyen GN, Everett JK, Kafle S, et al. A long-term study of AAV gene therapy in dogs with hemophilia a identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021 Jan;39(1):47–55. doi: 10.1038/s41587-020-0741-7
   PubMed Web of Science ®Google Scholar
• Lin KF, Chao J, Chao L. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995 Dec;26(6 Pt 1):847–53. doi: 10.1161/01.HYP.26.6.847
   PubMed Web of Science ®Google Scholar
• Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther. 1998 Jul 1;9(10):1429–1438. doi: 10.1089/hum.1998.9.10-1429
   PubMed Web of Science ®Google Scholar
• Cataliotti A, Tonne JM, Bellavia D, et al. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation. 2011 Mar 29;123(12):1297–1305. doi: 10.1161/CIRCULATIONAHA.110.981720
   PubMed Web of Science ®Google Scholar
• Tonne JM, Holditch SJ, Oehler EA, et al. Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease. Aging. 2014 Apr;6(4):311–319. doi: 10.18632/aging.100655
   PubMedGoogle Scholar
• Mariani JA, Smolic A, Preovolos A, et al. Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur J Heart Fail. 2011 Mar;13(3):247–53. doi: 10.1093/eurjhf/hfq234
   PubMed Web of Science ®Google Scholar
• Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009 Apr;15(3):171–181. doi: 10.1016/j.cardfail.2009.01.013
   PubMed Web of Science ®Google Scholar
• Jessup M, Greenberg B, Mancini D, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2±ATPase in patients with advanced heart failure. Circulation. 2011 Jul 19;124(3):304–313. doi: 10.1161/CIRCULATIONAHA.111.022889
   PubMed Web of Science ®Google Scholar
• Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016 Mar 19;387(10024):1178–1186. doi: 10.1016/S0140-6736(16)00082-9
   PubMed Web of Science ®Google Scholar
• Numata G, Takimoto E. Cyclic GMP and PKG signaling in heart failure. Front Pharmacol. 2022;13:792798. doi: 10.3389/fphar.2022.792798
   PubMed Web of Science ®Google Scholar
• Kansakar S, Guragain A, Verma D, et al. Soluble Guanylate Cyclase Stimulators in Heart Failure. Cureus. 2021 Sep;13(9):e17781. doi: 10.7759/cureus.17781
   PubMed Web of Science ®Google Scholar
• Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest. 2014 Nov;146(5):1274–1285. doi: 10.1378/chest.14-0106
   PubMed Web of Science ®Google Scholar
• Udelson JE, Lewis GD, Shah SJ, et al. Effect of Praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial. JAMA. 2020 Oct 20;324(15):1522–1531. doi: 10.1001/jama.2020.16641
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Greene SJ, Butler J, et al. Effect of Vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015 Dec 1;314(21):2251–2262. doi: 10.1001/jama.2015.15734
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020 May 14;382(20):1883–1893. doi: 10.1056/NEJMoa1915928
   PubMed Web of Science ®Google Scholar
• Chiles R, Al-Horani RA, Tomlinson B. Vericiguat: A New Hope for Heart Failure Patients. Cardiovasc Ther. 2022;2022:1–6. doi: 10.1155/2022/1554875
   Web of Science ®Google Scholar
• Blanton RM. cGMP signaling and modulation in heart failure. J Cardiovasc Pharmacol. 2020 May;75(5):385–398. doi: 10.1097/FJC.0000000000000749
   PubMed Web of Science ®Google Scholar
• Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011 Jan;4(1):8–17. doi: 10.1161/CIRCHEARTFAILURE.110.944694
   PubMed Web of Science ®Google Scholar
• Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011 Jul 12;124(2):164–174. doi: 10.1161/CIRCULATIONAHA.110.983866
   PubMed Web of Science ®Google Scholar
• Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013 Mar 27;309(12):1268–1277. doi: 10.1001/jama.2013.2024
   PubMed Web of Science ®Google Scholar
• Methawasin M, Strom J, Borkowski T, et al. Phosphodiesterase 9a inhibition in mouse models of diastolic dysfunction. Circ Heart Fail. 2020 May;13(5):e006609. doi: 10.1161/CIRCHEARTFAILURE.119.006609
   PubMed Web of Science ®Google Scholar
• Richards DA, Aronovitz MJ, Liu P, et al. CRD-733, a novel PDE9 (phosphodiesterase 9) inhibitor, reverses pressure overload-induced heart failure. Circ Heart Fail. 2021 Jan;14(1):e007300. doi: 10.1161/CIRCHEARTFAILURE.120.007300
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Docherty KF. Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides? J Am Coll Cardiol. 2019 Aug 20;74(7):902–904. doi: 10.1016/j.jacc.2019.07.008
   PubMed Web of Science ®Google Scholar
• Alzahri MS, Rohra A, Peacock WF. Nitrates as a Treatment of Acute Heart Failure. Card Fail Rev. 2016, May;2(1):51–55. doi: 10.15420/cfr.2016:3:3
   PubMedGoogle Scholar
• Loeb HS, Johnson G, Henrick A, et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative studies group. Circulation. 1993 Jun;87(6 Suppl):Vi78–87.
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004 Nov 11;351(20):2049–2057. doi: 10.1056/NEJMoa042934
   PubMed Web of Science ®Google Scholar
• Blanton RM, Takimoto E, Lane AM, et al. Protein kinase g iα inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc. 2012, Oct;1(5):e003731. doi: 10.1161/JAHA.112.003731
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ranek MJ, Lee DI, et al. Prevention of PKG1α oxidation augments cardioprotection in the stressed heart. J Clin Invest. 2015, Jun;125(6):2468–2472. doi: 10.1172/JCI80275
   PubMed Web of Science ®Google Scholar
• Nogi K, Ueda T, Matsue Y, et al. Effect of carperitide on the 1 year prognosis of patients with acute decompensated heart failure. ESC Heart Fail. 2022, Apr;9(2):1061–1070. doi: 10.1002/ehf2.13770
   PubMed Web of Science ®Google Scholar
• Nomura F, Kurobe N, Mori Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J. 2008, Nov;72(11):1777–1786. doi: 10.1253/circj.cj-07-0760
   PubMed Web of Science ®Google Scholar
• Hata N, Seino Y, Tsutamoto T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008, Nov;72(11):1787–93. doi: 10.1253/circj.CJ-08-0130
   PubMed Web of Science ®Google Scholar
• Matsue Y, Kagiyama N, Yoshida K, et al. Carperitide is associated with increased in-Hospital mortality in acute heart failure: a propensity score-matched analysis. J Card Fail. 2015, Nov;21(11):859–64. doi: 10.1016/j.cardfail.2015.05.007
   PubMed Web of Science ®Google Scholar
• Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial Natrecor Study Group. J Am Coll Cardiol. 1999, Jul;34(1):155–62. doi: 10.1016/S0735-1097(99)00184-9
   PubMed Web of Science ®Google Scholar
• Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure Nesiritide Study Group. N Engl J Med. 2000 Jul 27;343(4):246–253. doi: 10.1056/NEJM200007273430403
   PubMed Web of Science ®Google Scholar
• Meems LMG, Burnett JC Jr. Innovative therapeutics: Designer Natriuretic Peptides. JACC Basic Transl Sci. 2016, Dec;1(7):557–567. doi: 10.1016/j.jacbts.2016.10.001
   PubMedGoogle Scholar
• O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011 Jul 7;365(1):32–43. doi: 10.1056/NEJMoa1100171
   PubMed Web of Science ®Google Scholar
• Chen HH, Glockner JF, Schirger JA, et al. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol. 2012 Dec 4;60(22):2305–2312. doi: 10.1016/j.jacc.2012.07.056
   PubMed Web of Science ®Google Scholar
• Martin FL, Sangaralingham SJ, Huntley BK, et al. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One. 2012;7(12):e52422.
   PubMed Web of Science ®Google Scholar
• Lisy O, Huntley BK, McCormick DJ, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008 Jul 1;52(1):60–68. doi: 10.1016/j.jacc.2008.02.077
   PubMed Web of Science ®Google Scholar
• Lee CY, Chen HH, Lisy O, et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol. 2009, Jun;49(6):668–73. doi: 10.1177/0091270009336233
   PubMed Web of Science ®Google Scholar
• Kawakami R, Lee CYW, Scott C, et al. A human study to evaluate safety, tolerability, and cyclic GMP activating properties of Cenderitide in subjects with stable chronic heart failure. Clin Pharmacol Ther. 2018, Sep;104(3):546–552. doi: 10.1002/cpt.974
   PubMed Web of Science ®Google Scholar
• McKie PM, Cataliotti A, Boerrigter G, et al. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension. 2010, Dec;56(6):1152–1159. doi: 10.1161/HYPERTENSIONAHA.110.159210
   PubMed Web of Science ®Google Scholar
• McKie PM, Cataliotti A, Ichiki T, et al. M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. J Am Heart Assoc. 2014 Jan 2;3(1):e000206. doi: 10.1161/JAHA.113.000206
   PubMed Web of Science ®Google Scholar
• Chen HH, Neutel JM, Smith DH, et al. ZD100 a novel particulate-guanylyl-cyclase a receptor activator in human resistant “like” hypertension—A first in human study. J Card Fail. 2016;22(8):S33.
   PubMed Web of Science ®Google Scholar
• Pan S, Chen HH, Dickey DM, et al. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11282–11287. doi: 10.1073/pnas.0811851106
   PubMed Web of Science ®Google Scholar
• Seok HY, Chen J, Kataoka M, et al. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res. 2014 May 9;114(10):1585–1595. doi: 10.1161/CIRCRESAHA.114.303784
   PubMed Web of Science ®Google Scholar
• Arora P, Wu C, Khan AM, et al. Atrial natriuretic peptide is negatively regulated by microRNA-425. J Clin Invest. 2013, Aug;123(8):3378–3382. doi: 10.1172/JCI67383
   PubMed Web of Science ®Google Scholar
• Batkai S, Genschel C, Viereck J, et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur Heart J. 2021 Jan 7;42(2):192–201. doi: 10.1093/eurheartj/ehaa791
   PubMed Web of Science ®Google Scholar
• Täubel J, Hauke W, Rump S, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021 Jan 7;42(2):178–188. doi: 10.1093/eurheartj/ehaa898
   PubMed Web of Science ®Google Scholar
• Huang XH, Li JL, Li XY, et al. miR-208a in cardiac hypertrophy and remodeling. Front Cardiovasc Med. 2021;8:773314. doi: 10.3389/fcvm.2021.773314
   PubMed Web of Science ®Google Scholar
• Celik S, Sadegh MK, Morley M, et al. Antisense regulation of atrial natriuretic peptide expression. JCI Insight. 2019 Oct 3;4(19). doi: 10.1172/jci.insight.130978
   PubMed Web of Science ®Google Scholar
• Luna C, Li G, Qiu J, et al. MicroRNA-24 regulates the processing of latent TGFβ1 during cyclic mechanical stress in human trabecular meshwork cells through direct targeting of FURIN. J Cell Physiol. 2011, May;226(5):1407–1414. doi: 10.1002/jcp.22476
   PubMed Web of Science ®Google Scholar
• Wang X, Huang W, Liu G, et al. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J Mol Cell Cardiol. 2014 Sep;74:139–150
   PubMed Web of Science ®Google Scholar
• Vegter EL, van der Meer P, de Windt LJ, et al. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail. 2016 May;18(5):457–468. doi: 10.1002/ejhf.495
   PubMed Web of Science ®Google Scholar